Home > Insider Trading > Filing (0000899243-17-025508)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1701108	Spero Therapeutics Inc.	SPRO	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1721017	Vikas Goyal	C/O S.r. One, Limited 161 Washington Street, Suite 500 Conshohocken PA 19428		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-11-06	244,147	$0.00	244,147	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2017-11-06	246,272	$0.00	490,419	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2017-11-06	328,992	$0.00	819,411	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2017-11-06	606,024	$0.00	1,425,435	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2017-11-06	428,571	$14.00	1,854,006	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Junior preferred stock	Disposition	2017-11-06	1,483,784	$0.00	244,147	$0.00
Common Stock	Series A preferred stock	Disposition	2017-11-06	982,906	$0.00	246,272	$0.00
Common Stock	Series B preferred stock	Disposition	2017-11-06	1,250,000	$0.00	328,992	$0.00
Common Stock	Series C preferred stock	Disposition	2017-11-06	3,683,045	$0.00	606,024	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Reflects shares of the Issuer's common stock that were purchased in connection with the Issuer's initial public offering.
Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017). The preferred stock had no expiration date.
S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc, is the record holder of these shares reported herein. Vikas Goyal is a Principal at S.R. One, Limited and an employee of GlaxoSmithKline LLC, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc. Mr. Goyal disclaims beneficial ownership of all shares held by S.R. One, Limited and this report shall not be deemed an admission of beneficial ownership of such shares for the purpose of Section 16 or for any other purpose except to the extent of his pecuniary interest therein.